• 1
    ) Matsumoto, K., Yamamoto, T., Kamata, R. and Maeda, H. Pathogenesis of serratial infection: activation of the Hageman factor-prekallikrein cascade by serratial protease. J. Biochem., 96, 739746 (1984).
  • 2
    ) Kamata, R., Yamamoto, T., Matsumoto, K. and Maeda, H. A serratial protease causes vascular permeability reaction by activation of the Hageman factor-dependent pathway in guinea pigs. Infect. Immun., 48, 747753 (1985).
  • 3
    ) Matsumoto, K., Yamamoto, T., Kamata, R. and Maeda, H. Enhancement of vascular permeability upon serratial infection: activation of Hageman factor-kallikrein-kinin cascade. InKinins IV B.” ed. L. M.Greenbaum and H. S.Margolius, pp. 7178 (1986). Plenum Publishing Corp., New York .
  • 4
    ) Senger, D. R., Galli, S J., Dvorak, A. M., Perruzzi, C. A., Harvey, V. S. and Dvorak, H. F. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science, 219, 983985 (1983).
  • 5
    ) Senger, D. R., Perruzzi, C. A., Feder, J. and Dvorak, H. F. A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. Cancer Res., 46, 56295632 (1986).
  • 6
    ) Maeda, H., Takeshita, J. and Kanamaru, R. A lipophilic derivative of neocarzinostatin. A polymer conjugation an antitumor protein antibiotic. Int. J. Pept. Protein Res., 14, 8187 (1979).
  • 7
    ) Maeda, H., Ueda, M., Morinaga, T. and Matsumoto, T. Conjugation of poly (styrene-co-maleic acid) derivatives to the antitumor protein neocarzinostatin: pronounced improvements in pharmacological properties. J. Med. Chem., 28, 455461 (1985).
  • 8
    ) Matsumura, Y. and Maeda, H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res., 46, 63876392 (1986).
  • 9
    ) Maeda, H., Matsumura, Y., Oda, T. and Sasamoto, K. Cancer selective macromolecular therapeusis: tailoring of an antitumor protein drug. InProtein Tailoring for Food and Medical Uses,” ed. R. E.Feeney and J. R.Whitaker, pp. 353381 (1986). Marcel Dekker, New York .
  • 10
    ) Iwai, K., Maeda, H. and Konno, T. Use of oily contrast medium for selective drug targeting to tumor enhanced therapeutic effect and X-ray image. Cancer Res., 44, 21152121 (1984).
  • 11
    ) Konno, T., Maeda, H., Iwai, K., Tashiro, S., Maki, S., Morinaga, T., Mochinaga, M., Hiraoka, T. and Yokoyama, I. Effect of arterial administration of high molecular weight anticancer agent SMANCS with lipid lymphographic agent on hepatoma: a preliminary report. Eur. J. Cancer Clin. Oncol., 19, 10531065 (1984).
  • 12
    ) Konno, T., Maeda, H., Iwai, K., Maki, S., Tashiro, S., Uchida, M. and Miyauchi, Y. Selective targeting of anticancer drug and simultaneous image enhancement in solid tumors by arterially administered lipid contrast medium. Cancer, 54, 23672374 (1984).
  • 13
    ) Iwai, K., Maeda, H., Konno, T., Matsumura, Y., Yamashita, R., Yamasaki, K., Hirayama, S. and Miyauchi, Y. Tumor targeting by arterial administration of lipids: rabbit model with VX2 carcinoma in the liver. Anticancer Res., 7, 321328 (1987).
  • 14
    ) Suzuki, M., Takahashi, T. and Sato, T. Medical regression and its functional significance in tumor-supplying host arteries: a morphometric study of hepatic arteries in human liver with hepatocellular carcinoma. Cancer, 56, 444450 (1987).
  • 15
    ) Ondetti, M. A., Rubin, B. and Cushman, D. W. Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents. Science, 196, 441444 (1977).
  • 16
    ) Gross, D. M., Sweet, C. S., Ulm, E. H., Backlund, E. P., Morris, A. A., Weiz, D., Bohn, D. L., Wenger, H. C., Vassil, T. C. and Stone, C. A. Effect of N-[(s)-I-carboxy-3-phenylpropyl]L-Ala-L-Pro and its ethyl ester (MK-421) on angiotensin converting enzyme in vitro and angiotensin I pressor responses in vivo. J. Pharmacol. Exp. Therap. 216, 552557 (1981).
  • 17
    ) Plummer, T. H., Jr. and Ryan, T. J. A potent mercapto bi-product analogue inhibitor for human carboxypeptidase N. Biochem. Biophys. Res. Commun., 98, 448454 (1981).
  • 18
    ) Freer, R., Chang, J. and Greenbaum, L. M. Studies on leukokinins. III. pharmacological activities. Biochem. Pharmacol., 21, 31073110 (1972).
  • 19
    ) Maeda, H., Matsumura, Y. and Kato, H. Purification and identification of hydroxyprolyl3-bradykinin in ascitic fluid from a patient with gastric cancer. J. Biol. Chem., 263, 1605116054 (1988).
  • 20
    ) Hnatowich, D. J., Layne, W. W. and Childs, R. L. The preparation and labeling of DTPA-coupled albumin. Int. J. Appl. Radiat. Isot., 33, 327332 (1982).
  • 21
    ) Meares, C. F. Attaching metal ions to antibodies. InProtein Tailoring for Food and Medical Uses,” ed. R. E.Feeney and J. R.Whitaker, pp. 339352 (1986). Marcel Dekker, New York .
  • 22
    ) Halpern, S., Stern, P., Hagan, P., Chen, A., Frincke, J., Bartholomew, R., David, G. and Adams, T. Labeling of monoclonal antibodies with indium 111 technique and advantages compared to radioiodine labeling. InRadioimmunoimaging and Radioimmunotherapy,” ed. S. W.Burchiel and B. A.Rhodes, pp. 197205 (1983). Elsevier Science Publ. Co. Inc., New York .
  • 23
    ) Uchida, Y., Tanaka, K., Harada, Y., Ueno, A. and Katori, M. Activation of plasma kallikrein-kinin system and its significant role in pleural fluid accumulation of rat carrageenin-induced pleurisy. Inflammation, 7, 121131 (1983).
  • 24
    ) Fantone, J. C., Schrier, D. and Weingarten, B. Inhibition of vascular permeability changes in rats by captopril. J. Clin. Invest., 69, 12071211 (1982).
  • 25
    ) Greenbaum, L. M., Grebow, P., Johnston, M., Prakash, A. and Semente, G. Pepstatin — an inhibitor of leukokinin formation and ascitic fluid accumulation. Cancer Res., 35, 706710 (1975).